Pictor’s Proteomics Platform Offers Promising Advancement for Detecting Mycoplasma bovis in Cattle
New research highlights the Pictor  PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced…
Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next…
Pictor Secures Funding to Accelerate U.S. Expansion through Partner-Informed Proteomics Solutions
CARLSBAD, Calif., Sept. 23, 2025 /PRNewswire/ --Â Pictor Holdings Inc., a global leader…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters…
Evosep Joins P4ML to Power Worlds Largest Multi-Omic Human Health Study of Two Million Samples
SAINT-MALO, France, June 17, 2025 (GLOBE NEWSWIRE) -- Evosep®, a global leader…
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT,…